<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="57313"><DrugName>dalantercept</DrugName><DrugNamesKey><Name id="42955035">dalantercept</Name></DrugNamesKey><DrugSynonyms><Name><Value>ACE-041</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>chimeric receptor TGF beta antagonist (sc, solid tumors/multiple myeloma/AMD), Acceleron</Value></Name><Name><Value>RAP-041</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>recombinant ALK-1 signaling inhibitor (angiogenesis), Acceleron</Value></Name><Name><Value>Alk1-Fc</Value></Name><Name><Value>dalantercept</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1009646">Acceleron Pharma Inc</CompanyOriginator><CompaniesSecondary><Company id="1009646">Acceleron Pharma Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="57313" type="Drug"><TargetEntity id="454400" type="siDrug">Dalantercept</TargetEntity><TargetEntity id="651883" type="siDrug">RAP-041</TargetEntity></SourceEntity><SourceEntity id="1009646" type="Company"><TargetEntity id="4296015497" type="organizationId">Acceleron Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="1226" type="ciIndication"><TargetEntity id="4830" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1705" type="ciIndication"><TargetEntity id="10014733" type="MEDDRA"></TargetEntity><TargetEntity id="D016889" type="MeSH"></TargetEntity><TargetEntity id="-49801714" type="omicsDisease"></TargetEntity><TargetEntity id="597" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1767" type="ciIndication"><TargetEntity id="D006528" type="MeSH"></TargetEntity><TargetEntity id="88673" type="ORPHANET"></TargetEntity><TargetEntity id="-1116061312" type="omicsDisease"></TargetEntity><TargetEntity id="1973" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1828" type="ciIndication"><TargetEntity id="C90.0" type="ICD10"></TargetEntity><TargetEntity id="10028228" type="MEDDRA"></TargetEntity><TargetEntity id="D009101" type="MeSH"></TargetEntity><TargetEntity id="29073" type="ORPHANET"></TargetEntity><TargetEntity id="-18870694" type="omicsDisease"></TargetEntity><TargetEntity id="710" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2243" type="ciIndication"><TargetEntity id="C57.0" type="ICD10"></TargetEntity><TargetEntity id="10016180" type="MEDDRA"></TargetEntity><TargetEntity id="D005185" type="MeSH"></TargetEntity><TargetEntity id="-33569282" type="omicsDisease"></TargetEntity><TargetEntity id="600" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="28" type="ciIndication"><TargetEntity id="10003246" type="MEDDRA"></TargetEntity><TargetEntity id="D001168" type="MeSH"></TargetEntity><TargetEntity id="-1504014133" type="omicsDisease"></TargetEntity><TargetEntity id="720" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3083" type="ciIndication"><TargetEntity id="C48" type="ICD10"></TargetEntity><TargetEntity id="10061344" type="MEDDRA"></TargetEntity><TargetEntity id="D010534" type="MeSH"></TargetEntity><TargetEntity id="-745704479" type="omicsDisease"></TargetEntity><TargetEntity id="633" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3467" type="ciIndication"><TargetEntity id="1233" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3673" type="ciIndication"><TargetEntity id="5572" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"></TargetEntity><TargetEntity id="10033128" type="MEDDRA"></TargetEntity><TargetEntity id="D010051" type="MeSH"></TargetEntity><TargetEntity id="-1370909262" type="omicsDisease"></TargetEntity><TargetEntity id="626" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="377" type="Action"><TargetEntity id="2805" type="Mechanism">TGF-beta Inhibitors</TargetEntity><TargetEntity id="5382" type="Mechanism">Transforming Growth Factor beta (TGFbeta) Superfamily Proteins Inhibitors</TargetEntity><TargetEntity id="2515" type="Mechanism">Transforming Growth Factor (TGF)-beta Receptor Inhibitors</TargetEntity></SourceEntity><SourceEntity id="61" type="Action"><TargetEntity id="885" type="Mechanism">Angiogenesis Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4580" type="Action"><TargetEntity id="3009" type="Mechanism">Activin Receptor Like Kinase 1 (ALK1) Inhibitors</TargetEntity><TargetEntity id="3650" type="Mechanism">Anti-ALK1</TargetEntity><TargetEntity id="3783" type="Mechanism">Activin Receptor Like Kinase 1 (ALK1) Group Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00096" type="ciTarget"><TargetEntity id="1043155650943" type="siTarget">Serine/threonine-protein kinase receptor R3</TargetEntity><TargetEntity id="-1908094858" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00218" type="ciTarget"><TargetEntity id="294503565273023" type="siTarget">Bone morphogenetic protein 10</TargetEntity><TargetEntity id="-1681894664" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00223" type="ciTarget"><TargetEntity id="54169185426583" type="siTarget">Growth/differentiation factor 2</TargetEntity><TargetEntity id="8026" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1226">Age related macular degeneration</Indication><Indication id="1705">Endometrioid carcinoma</Indication><Indication id="1767">Hepatocellular carcinoma</Indication><Indication id="1828">Multiple myeloma</Indication><Indication id="2243">Fallopian tube cancer</Indication><Indication id="28">Arthritis</Indication><Indication id="3083">Peritoneal tumor</Indication><Indication id="3467">Metastatic renal cancer</Indication><Indication id="3673">Metastatic head and neck cancer</Indication><Indication id="651">Cancer</Indication><Indication id="725">Solid tumor</Indication><Indication id="799">Ovary tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="377">TGF beta receptor antagonist</Action><Action id="4580">Alk-1 protein kinase inhibitor</Action><Action id="6871">Bone morphogenetic protein-10 ligand modulator</Action><Action id="6868">Bone morphogenetic protein-9 ligand modulator</Action></ActionsPrimary><ActionsSecondary><Action id="7293">Synergist</Action><Action id="62255">Anticancer protein kinase inhibitor</Action><Action id="61">Angiogenesis inhibitor</Action><Action id="15148">Ocular antineovascularisation agent</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="342">Receptor fusion</Technology><Technology id="180">Antibody fragment</Technology><Technology id="83">Protein chimeric</Technology><Technology id="84">Protein fusion</Technology></Technologies><EphmraCodes><Ephmra><Code>S1P</Code><Name>Ocular antineovascularisation products</Name></Ephmra></EphmraCodes><LastModificationDate>2018-05-16T07:48:44.000Z</LastModificationDate><ChangeDateLast>2017-06-14T00:00:00.000Z</ChangeDateLast><AddedDate>2007-05-09T11:26:21.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1009646" linkType="Company"&gt;Acceleron&lt;/ulink&gt; was developing dalantercept (ACE-041, RAP-041), a chimeric protein consisting of a soluble activin receptor-like kinase 1 (ALK1) receptor with an Fc receptor, which inhibits angiogenesis by preventing the interaction of members of the TGFbeta protein superfamily (BMP9 and BMP10) with ALK1 to prevent signalling through the ALK1 receptor, for the potential sc treatment of  cancer, primarily metastatic renal cell carcinoma and hepatocellular cancer (HCC)  [&lt;ulink linkID="792267" linkType="Reference"&gt;792267&lt;/ulink&gt;], [&lt;ulink linkID="1084871" linkType="Reference"&gt;1084871&lt;/ulink&gt;],  [&lt;ulink linkID="1505664" linkType="Reference"&gt;1505664&lt;/ulink&gt;], [&lt;ulink linkID="1585061" linkType="Reference"&gt;1585061&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2012, a phase II study (DART) was initiated in metastatic renal cell carcinoma   [&lt;ulink linkID="1366194" linkType="Reference"&gt;1366194&lt;/ulink&gt;], [&lt;ulink linkID="1366085" linkType="Reference"&gt;1366085&lt;/ulink&gt;]; in February 2015, positive data from part 1 of the DART study were presented.  At that time, part 2 of the study was open for enrollment [&lt;ulink linkID="1637467" linkType="Reference"&gt;1637467&lt;/ulink&gt;], [&lt;ulink linkID="1637707" linkType="Reference"&gt;1637707&lt;/ulink&gt;]; in June 2017, negative topline results were reported; at that time,  based on the lack of efficacy, Acceleron discontinued the development of dalantercept  [&lt;ulink linkID="1937131" linkType="Reference"&gt;1937131&lt;/ulink&gt;].  In June 2014, the phase Ib portion of a phase I/II trial for HCC was initiated [&lt;ulink linkID="1585061" linkType="Reference"&gt;1585061&lt;/ulink&gt;]; in June 2017, the trial was presumed to have been terminated  [&lt;ulink linkID="1937131" linkType="Reference"&gt;1937131&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company was previously developing the drug in other cancer settings, including for endometrial cancer, squamous cell carcinoma of the head and neck (SCCHN) and ovarian cancer [&lt;ulink linkID="792267" linkType="Reference"&gt;792267&lt;/ulink&gt;]. In September 2012, a phase II trial in endometrial cancer was initiated  [&lt;ulink linkID="1340815" linkType="Reference"&gt;1340815&lt;/ulink&gt;], [&lt;ulink linkID="1340673" linkType="Reference"&gt;1340673&lt;/ulink&gt;]; however by December 2013, dalantercept had shown no sufficient activity to warrant development as a monotherapy for endometrial cancer and was not to advance to the second trial stage [&lt;ulink linkID="1505664" linkType="Reference"&gt;1505664&lt;/ulink&gt;]. In October 2011, a phase II trial in squamous cell carcinoma of the head and neck (SCCHN) began [&lt;ulink linkID="1233940" linkType="Reference"&gt;1233940&lt;/ulink&gt;]; by March 2017, development for SCCHN was stopped as dalantercept had not shown sufficient activity to warrant development as a monotherapy for this indication [&lt;ulink linkID="1904977" linkType="Reference"&gt;1904977&lt;/ulink&gt;].  In November 2012, a phase II study was initiated in recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma  [&lt;ulink linkID="1366201" linkType="Reference"&gt;1366201&lt;/ulink&gt;], [&lt;ulink linkID="1366085" linkType="Reference"&gt;1366085&lt;/ulink&gt;]; in September 2014, interim data were reported [&lt;ulink linkID="1596370" linkType="Reference"&gt;1596370&lt;/ulink&gt;]; by March 2017, development for ovarian cancer was stopped as dalantercept had not shown sufficient activity to warrant development as a monotherapy for this indication [&lt;ulink linkID="1904977" linkType="Reference"&gt;1904977&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company was also previously investigating the drug in non-cancer settings, including age-related macular degeneration (AMD) and arthritis [&lt;ulink linkID="1219307" linkType="Reference"&gt;1219307&lt;/ulink&gt;], [&lt;ulink linkID="1050268" linkType="Reference"&gt;1050268&lt;/ulink&gt;].  In September 2011, the drug was listed as being in phase I development for AMD [&lt;ulink linkID="1219307" linkType="Reference"&gt;1219307&lt;/ulink&gt;]; however in June 2013, this indication was no longer listed on the company pipeline [&lt;ulink linkID="1440168" linkType="Reference"&gt;1440168&lt;/ulink&gt;]. The company was previously investigating the drug for arthritis [&lt;ulink linkID="667869" linkType="Reference"&gt;667869&lt;/ulink&gt;], [&lt;ulink linkID="792267" linkType="Reference"&gt;792267&lt;/ulink&gt;], [&lt;ulink linkID="1085101" linkType="Reference"&gt;1085101&lt;/ulink&gt;], [&lt;ulink linkID="1084871" linkType="Reference"&gt;1084871&lt;/ulink&gt;]. However, no further development was reported for this indication since May 2006.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In March 2017, Acceleron stated that  it held an issued patent covering the dalantercept composition of matter in the US, which expires in 2029 exclusive of possible&lt;br&gt;&lt;/br&gt;patent term extensions; at that time, the company had additional pending patent applications in that region. Acceleron also held additional issued patents and pending patent applications covering composition of matter in other jurisdictions worldwide, including Europe, Australia, Canada, Japan, China, South Korea, Brazil, Mexico, Russia and India with expected expiration, if issued, in 2027 or 2029 exclusive of possible patent term extensions. Acceleron also held an issued patent covering the treatment of tumor angiogenesis by administration of dalantercept in the US and similar patents issued or pending in other jurisdictions worldwide including Europe, Japan, China, South Korea, Brazil, Mexico, Russia and India which were expected expiry in 2027 exclusive of possible patent term extensions. The company also held patent applications directed to a variety of other uses for dalantercept including the treatment of renal cell carcinoma with a combination of dalantercept and a VEGF-targeted tyrosine kinase inhibitor. This patent application was jointly invented and owned with the &lt;ulink linkID="24877" linkType="Company"&gt;Beth Israel Deaconess Medical Center&lt;/ulink&gt;, with Acceleron having secured an exclusive license to the BIDMC rights. The expected expiration date for these patent applications, if issued, is 2033 plus any available extensions of term. Additionally, Acceleron held joint patent rights related to the treatment of pancreatic tumors with dalantercept under a license agreement with &lt;ulink linkID="21091" linkType="Company"&gt;Ludwig Institute for Cancer Research&lt;/ulink&gt;, if issued, these patent rights were expected to expire in 2029 [&lt;ulink linkID="1904977" linkType="Reference"&gt;1904977&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;By November 2015, Fast Track designation had been granted for dalantercept in combination with &lt;ulink linkID="39209" linkType="Drug"&gt;axitinib&lt;/ulink&gt; for the treatment of patients with advanced renal cell carcinoma [&lt;ulink linkID="1709863" linkType="Reference"&gt;1709863&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In May 2014, a phase Ib trial for dalantercept in combination with &lt;ulink linkID="29831" linkType="Drug"&gt;sorafenib&lt;/ulink&gt; in patients with HCC was planned  [&lt;ulink linkID="1505664" linkType="Reference"&gt;1505664&lt;/ulink&gt;]; in June 2014, the open-label phase I/II trial (&lt;ulink linkID="165517" linkType="Protocol"&gt;NCT02024087&lt;/ulink&gt;; A041-05, ACE-041) in 20 patients was initiated in the US. The trial was expected to be completed in September 2017 [&lt;ulink linkID="1584893" linkType="Reference"&gt;1584893&lt;/ulink&gt;], [&lt;ulink linkID="1585061" linkType="Reference"&gt;1585061&lt;/ulink&gt;]. In January 2015, clinical data were presented from this ongoing study at the 2015 ASCO Gastrointestinal Cancer Symposium in San Francisco, CA.  In the first two cohorts, patients (n = 3 to 6 each) would receive sc dalantercept (0.6 and 0.9 mg/kg, respectively) q3w + sorafenib (400 mg po, qd). In the cohort 3, patients (n = 3 to 6) would receive dalantercept (0.9 mg/kg, sc, q3w) with sorafenib (400 mg po, bid). An expansion cohort would enroll 10 to 20 patients at or below MTD level. At that time, enrollment was completed for cohort 1 and was ongoing for cohort 2 [&lt;ulink linkID="1632703" linkType="Reference"&gt;1632703&lt;/ulink&gt;]. In November 2016, the study was ongoing but not recruiting patients [&lt;ulink linkID="1585061" linkType="Reference"&gt;1585061&lt;/ulink&gt;]. In June 2017, the trial was presumed to have been terminated following the discontinuing of development of dalantercept in June 2017 [&lt;ulink linkID="1937131" linkType="Reference"&gt;1937131&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2012, a two-part, phase II study (&lt;ulink linkID="98352" linkType="Protocol"&gt;NCT01727336&lt;/ulink&gt;, A041-04, ACE-041, DART) of dalantercept in combination with &lt;ulink linkID="39209" linkType="Drug"&gt;axitinib&lt;/ulink&gt; was initiated in patients with metastatic renal cell carcinoma, in which part 1 was a dose-escalation study and part 2 was an open-label, randomized study. At that time, the study was expected to complete in December 2018 [&lt;ulink linkID="1366194" linkType="Reference"&gt;1366194&lt;/ulink&gt;], [&lt;ulink linkID="1366085" linkType="Reference"&gt;1366085&lt;/ulink&gt;]. In November 2013, enrollment was completed for the dose-escalation stage of the trial [&lt;ulink linkID="1496975" linkType="Reference"&gt;1496975&lt;/ulink&gt;]; in December 2013, the patient enrollment in the expansion stage had begun [&lt;ulink linkID="1505664" linkType="Reference"&gt;1505664&lt;/ulink&gt;]. In May 2014, interim data from the part 1 dose-escalation and expansion cohorts were reported. The combination was found to be safe and well-tolerated. Of the 20 evaluable patients, 25% of patients achieved objective response and 50% of patients showed stable disease. In the study, the overall disease control rate was 75% [&lt;ulink linkID="1557044" linkType="Reference"&gt;1557044&lt;/ulink&gt;]. In June 2014, further results from 26 patients were presented at the 50th ASCO meeting in Chicago, IL. The 0.9-mg/kg dose of dalantercept was selected as the recommended phase II dose. In the overall population, partial response and disease control rates were 25 and 55%, respectively, and stable disease was observed in 50% of patients [&lt;ulink linkID="1562799" linkType="Reference"&gt;1562799&lt;/ulink&gt;]. In February 2015, data from the first part of the DART study were presented at the ASCO 2015 Genitourinary Cancers Symposium held in Orlando, FL. In 28 patients, objective response rate and disease control rate at 6 months were found to be 25 and 57.1% respectively, and 60.7% of the patients showed stable disease. The preliminary median progression-free (PFS) duration was 8.3 months. At that time, 130-patient, double-blind, part 2 study was open for enrollment, and 0.9 mg/kg of dalantercept was selected as the dose level. The median PFS of the 0.9 mg/kg cohort was not yet reached [&lt;ulink linkID="1637467" linkType="Reference"&gt;1637467&lt;/ulink&gt;], [&lt;ulink linkID="1637707" linkType="Reference"&gt;1637707&lt;/ulink&gt;]. In  February 2015, further clinical data from part 1 were presented at the ASCO Genitourinary Symposium in Orlando, FL. In 1.2 mg/kg dose level, one DLT of grade 3 abdominal and back pain and also dalantercept associated edema events including peripheral edema, fluid overload, ascites and pleural effusion were observed [&lt;ulink linkID="1637902" linkType="Reference"&gt;1637902&lt;/ulink&gt;]. In June 2015, part 2 was actively enrolling patients nationwide at approximately 60 sites [&lt;ulink linkID="1666275" linkType="Reference"&gt;1666275&lt;/ulink&gt;]. In June 2015, data from the phase I portion were presented at the 51st ASCO meeting in Chicago, IL. Partial response was seen in 33.3, 33.3 and 15.4% of patients; stable disease was seen in 33.3, 66.7 and 69.2% of patients; progressive disease was seen in 33.3, 0 and 15.4% of patients in the dalantercept 0.6, 0.9 or 1.2 mg/kg dose groups, respectively [&lt;ulink linkID="1662673" linkType="Reference"&gt;1662673&lt;/ulink&gt;]. In November 2015, further clinical data from 29 patients were presented at the 14th International Kidney Cancer Symposium in Miami, FL. DLTs or grade 4/5 related adverse events were not reported. At 12 months, the PFS and overall survival in the 0.9 mg/kg cohort were 50 and 89%, respectively [&lt;ulink linkID="1730013" linkType="Reference"&gt;1730013&lt;/ulink&gt;]. In November 2016, enrollment was ongoing in part 2 of the study [&lt;ulink linkID="1869813" linkType="Reference"&gt;1869813&lt;/ulink&gt;]. In June 2017, negative topline results were reported from 131 enrolled patients demonstrating that the trial  did not meet its primary endpoint; based  on the all-treated patient population (n = 119), the median PFS for dalantercept plus axitinib was 6.8 months versus 5.6 months for placebo plus axitinib. The confirmed ORR for dalantercept plus axitinib was 19% versus 25% for placebo plus axitinib [&lt;ulink linkID="1937131" linkType="Reference"&gt;1937131&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2011, an open-label, phase II study (&lt;ulink linkID="81800" linkType="Protocol"&gt;NCT01458392&lt;/ulink&gt;; A041-03) was initiated in patients with recurrent or metastatic SCCHN  (n = 46) in the US, to assess the safety and efficacy of dalantercept monotherapy. The primary endpoint was objective response rate [&lt;ulink linkID="1233940" linkType="Reference"&gt;1233940&lt;/ulink&gt;]. In  May 2014, were presented at the 50th ASCO meeting in Chicago, IL.In 40 evaluable patients, 1 patient achieved partial response, 17 had stable disease and 22 had progressive disease. The disease control rate was 32.5%. The median progression-free survival and median overall survival durations were 1.4 and 8.9 months, respectively. The median overall survival was higher in the 1.2 mg/kg dalantercept cohort (9.5 months) compared with the 0.6 mg/kg dalantercept cohort (7.1 months) [&lt;ulink linkID="1562051" linkType="Reference"&gt;1562051&lt;/ulink&gt;], [&lt;ulink linkID="1557044" linkType="Reference"&gt;1557044&lt;/ulink&gt;]. In September 2015, the study was completed [&lt;ulink linkID="1233940" linkType="Reference"&gt;1233940&lt;/ulink&gt;].  By March 2017, development for squamous cell carcinoma of the head and neck was stopped as dalantercept had not shown sufficient activity to warrant development as a monotherapy for this indication [&lt;ulink linkID="1904977" linkType="Reference"&gt;1904977&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2011, it was reported at the 13th International Symposium of Anti-Angiogenic Therapy in San Diego, CA that phase II clinical trials in ovarian cancer were being planned [&lt;ulink linkID="1169254" linkType="Reference"&gt;1169254&lt;/ulink&gt;].  In November 2012, an open-label, single group assignment, phase II study (&lt;ulink linkID="96849" linkType="Protocol"&gt;NCT01720173&lt;/ulink&gt;, GOG-0170R) to evaluate safety and efficacy of dalantercept was initiated in patients (expected n = 43) with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. At that time, the study was expected to complete in October 2015 [&lt;ulink linkID="1366201" linkType="Reference"&gt;1366201&lt;/ulink&gt;], [&lt;ulink linkID="1366085" linkType="Reference"&gt;1366085&lt;/ulink&gt;]; by December 2013, patient enrolment had been completed in the first part of the trial [&lt;ulink linkID="1505664" linkType="Reference"&gt;1505664&lt;/ulink&gt;]. In September 2014, data from an interim report for the two-part study were reported. A total of six patients were progression free without any non-protocol therapy, for greater than 6 months in the first part of the study. Based on these results, patients were not be enrolled in the second part of the trial [&lt;ulink linkID="1596370" linkType="Reference"&gt;1596370&lt;/ulink&gt;]. By March 2017, development for ovarian cancer was stopped as dalantercept had not shown sufficient activity to warrant development as a monotherapy for this indication [&lt;ulink linkID="1904977" linkType="Reference"&gt;1904977&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2011, it was reported at the 13th International Symposium of Anti-Angiogenic Therapy in San Diego, CA that phase II clinical trials endometrial cancer were being planned [&lt;ulink linkID="1169254" linkType="Reference"&gt;1169254&lt;/ulink&gt;]. In September 2012, a multicenter, open-label phase II trial (&lt;ulink linkID="89262" linkType="Protocol"&gt;NCT01642082&lt;/ulink&gt;; CDR0000736764, GOG-0229N) in patients  (expected n = 52) with recurrent or persistent endometrial carcinoma  was initiated in the US. At that time, the trial was expected to complete in November 2013 [&lt;ulink linkID="1340815" linkType="Reference"&gt;1340815&lt;/ulink&gt;], [&lt;ulink linkID="1340673" linkType="Reference"&gt;1340673&lt;/ulink&gt;]; however in November 2013,  the trial was suspended as dalantercept had shown no sufficient activity to warrant development as a monotherapy for endometrial cancer  and the company confirmed that it would not advance to the second stage of this trial [&lt;ulink linkID="1340815" linkType="Reference"&gt;1340815&lt;/ulink&gt;], [&lt;ulink linkID="1505664" linkType="Reference"&gt;1505664&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In October 2009, a phase I open-label, multiple-dose, dose-escalation, safety study (&lt;ulink linkID="61131" linkType="Protocol"&gt;NCT00996957&lt;/ulink&gt;; A041-01) was initiated in the US in patients (n = 66) with advanced solid tumors or relapsed/refractory multiple myeloma. The study was expected to be completed in November 2010 [&lt;ulink linkID="1050268" linkType="Reference"&gt;1050268&lt;/ulink&gt;]. Along with safety and tolerability, pharmacokinetics and preliminary antitumor activity would be assessed [&lt;ulink linkID="1054630" linkType="Reference"&gt;1054630&lt;/ulink&gt;]. In November 2010, interim clinical data were presented at the 22nd EORTC-NCI-AACR Symposium in Berlin, Germany. By that time, five dose levels (0.1 to 1.6 mg/kg) completed. Of 19 patients, 3 had their disease stabilized. One patient enrolled at the 1.6 mg/kg dose level, had a positive major response with an observation of tumor metabolic activity reduction. The t1/2 was approximately 10 to 15 days, while the Tmax was between 4 and 7 days. Dalantercept (sc, q3w) was generally well tolerated with no DLTs with one case of grade 3 congestive heart failure. At that time, the drug was being tested at the dose level 3.2 mg/kg, which is intended for future phase II studies [&lt;ulink linkID="1145975" linkType="Reference"&gt;1145975&lt;/ulink&gt;], [&lt;ulink linkID="1149307" linkType="Reference"&gt;1149307&lt;/ulink&gt;]. In February 2011, further data from 37 patients were presented at the 13th International Symposium of Anti-Angiogenic Therapy in San Diego, CA. An MTD of 1.6 mg/kg (sc, q3w) was established; DLTs included congestive heart failure, fatigue, edema and nausea [&lt;ulink linkID="1169254" linkType="Reference"&gt;1169254&lt;/ulink&gt;]. In April 2011, similar clinical data were presented at the 102nd AACR meeting in Orlando, FL [&lt;ulink linkID="1177377" linkType="Reference"&gt;1177377&lt;/ulink&gt;]. In June 2011, similar clinical data were presented at the 47th ASCO meeting in Chicago, IL. In the study, dalantercept  exhibited antitumor activity with 1 patient achieving a partial response and 8 patients   stable disease (12 weeks)  [&lt;ulink linkID="1195395" linkType="Reference"&gt;1195395&lt;/ulink&gt;].    At that time, the trial was ongoing but not recruiting participants. Completion of the trial was expected in October 2011 [&lt;ulink linkID="1050268" linkType="Reference"&gt;1050268&lt;/ulink&gt;]. In February 2012, data from patients with SCCHN enrolled in the trial were presented at the 2012 Multidisciplinary Head and Neck Cancer Symposium in Phoenix, AZ. One SCCHN patient had a partial response of 32.5% decrease in target lesion size and 44% decrease in tumor metabolic activity on FDG-ET and a second patient had a minor response of 28.9 % decrease in target lesion size and 19% decrease in tumor metabolic activity on FDG-ET. The third patient had progressive disease after one cycle [&lt;ulink linkID="1263489" linkType="Reference"&gt;1263489&lt;/ulink&gt;]. In April 2012, similar data were presented at  the 103rd AACR meeting in Chicago, IL [&lt;ulink linkID="1277421" linkType="Reference"&gt;1277421&lt;/ulink&gt;]. In October  2012, the study was completed [&lt;ulink linkID="1050268" linkType="Reference"&gt;1050268&lt;/ulink&gt;]. In January 2014, similar data were published and further data demonstrated that the drug was well tolerated up to 1.6 mg/kg with a favourable safety profile [&lt;ulink linkID="1529063" linkType="Reference"&gt;1529063&lt;/ulink&gt;], [&lt;ulink linkID="1529353" linkType="Reference"&gt;1529353&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2014, the company expected to initiate clinical trials in additional cancer including colorectal and brain cancer in 2H14 [&lt;ulink linkID="1529063" linkType="Reference"&gt;1529063&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;  In October 2007, the company expected the drug to enter clinical testing in 2H08 [&lt;ulink linkID="845620" linkType="Reference"&gt;845620&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2015, preclinical data were published. Data demonstrated that the drug displayed stable disease in RIP-TAg2 mice, when compared  with tumors in control-treated mice that consistently presented with overt progressive disease. The drug  did not display hypoxia, using CA IX or HIF1alpha expression as proxies for low tissue oxygenation. Pancreatic neuroendocrine tumorigenesis (NET) disseminated predominantly to sentinel lymph nodes in the mesentery and to the liver. The rate of metastatic dissemination to the liver decreased by 86% compared with treatment with control IgG, upon long-term administration of neoadjuvant therapy. When compared to an anti-VEGF therapy, which induced an increased rate of metastasis, ALK1 inhibition caused regression of preformed hepatic NET foci in RIP-TAg2 mice from an average of 8.1 to 2.8 foci per histologic section and the rate of overall survival at 16 weeks of age was also increased from 27%. In MMTV-PyMT genetically engineered mouse model, the drug  reduced metastatic dissemination to the lung. A total of    87% decrease in metastatic colonization of the lung was observed. The drug reduced the metastatic success rate to the lung by 87%, in experimental mammary carcinoma, in EO771-bearing mice. A combined therapeutic regimen of the drug and &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; inhibited tumor growth and metastatic dissemination [&lt;ulink linkID="1670223" linkType="Reference"&gt;1670223&lt;/ulink&gt;], [&lt;ulink linkID="1670352" linkType="Reference"&gt;1670352&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2015, preclinical data were presented at the 2015 ASCO Gastrointestinal Cancer Symposium in San Francisco, CA.​  Dalantercept (10 mg/kg biw) in combination with sorafenib (5 to 15 mg/kg, qd) showed additive tumor growth inhibition when compared with single agents alone in BEL-7402 HCC xenograft tumor models [&lt;ulink linkID="1632703" linkType="Reference"&gt;1632703&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2014, preclinical data were presented at the 105th AACR meeting in San Diego, CA. In vivo, dalantercept in combination with &lt;ulink linkID="51933" linkType="Drug"&gt;cisplatin&lt;/ulink&gt; showed additive anti-tumor effect with 59% tumor growth inhibition on day 30 when compared with either of the single agents [&lt;ulink linkID="1538589" linkType="Reference"&gt;1538589&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2012,  data from  sudies performed in renal cell carcinoma models were presented at the 103rd AACR meeting in Chicago, IL. In the treatment-naive A498 xenograft mouse model, ACE-041 alone delayed tumor growth when compared with vehicle. ACE-041 alone showed no activity in the 786-O model; however, in A498 and the 786-O tumor xenograft models, the combination ACE-041 and &lt;ulink linkID="12973" linkType="Drug"&gt;sunitinib&lt;/ulink&gt; slowed the tumor growth to a greater extent than either agent alone or vehicle.  Perfusion imaging of these tumors revealed that ACE-041 and sunitinib combination lowered perfusion more than sunitinib-treated tumors [&lt;ulink linkID="1277690" linkType="Reference"&gt;1277690&lt;/ulink&gt;], [&lt;ulink linkID="1277421" linkType="Reference"&gt;1277421&lt;/ulink&gt;]. In April 2013, further data were presented at the 104th AACR Annual Meeting in Washington, DC. When compared with the vehicle, intraperitoneal administration of dalantercept (10 mg/kg tiw) down-regulated ld1 expression in endothelial cells of a nude mice bearing A498 xenografts. The vascular network of A498 tumor xenografts was altered with dalantercept. In A498 xenografts, the frequency of small vessels was reduced by dalantercept when compared with the vehicle [&lt;ulink linkID="1402333" linkType="Reference"&gt;1402333&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2010, preclinical data were reported showing the drug decreased tumor burden and angiogenesis in melanoma, pancreatic islet and breast cancer models. It was reported that tumor tissue has elevated expression of activin receptor-like kinase 1 (ALK1) receptor signalling, which is inhibited by the drug [&lt;ulink linkID="1084871" linkType="Reference"&gt;1084871&lt;/ulink&gt;], [&lt;ulink linkID="1085100" linkType="Reference"&gt;1085100&lt;/ulink&gt;], [&lt;ulink linkID="1085101" linkType="Reference"&gt;1085101&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2009, preclinical data were presented at the 100th AACR Meeting in Denver, CO. Further studies, both in vivo and in vitro, showing the compounds anti-angiogenic properties were presented, including tumor reduction effects in a breast cancer model [&lt;ulink linkID="994423" linkType="Reference"&gt;994423&lt;/ulink&gt;], [&lt;ulink linkID="1001371" linkType="Reference"&gt;1001371&lt;/ulink&gt;], [&lt;ulink linkID="1001400" linkType="Reference"&gt;1001400&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2009, data were presented at the 11th International Anti-Angiogenic Agents Symposium in San Diego, CA.  Results in MDA-MB-231 and MCF-7 xenografts were orthotopic and decreased microvessel density (MVD), respectively [&lt;ulink linkID="984602" linkType="Reference"&gt;984602&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2007, preclinical  studies had demonstrated that systemic administration of dalantercept results in inhibition of both VEGF- and FGF-induced angiogenesis [&lt;ulink linkID="792265" linkType="Reference"&gt;792265&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2006, preclinical investigations into antiangiogenics were underway [&lt;ulink linkID="667869" linkType="Reference"&gt;667869&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2013-12-03T00:00:00.000Z</StatusDate><Source id="1505664" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3467">Metastatic renal cancer</Indication><StatusDate>2017-06-12T00:00:00.000Z</StatusDate><Source id="1937131" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2017-06-12T00:00:00.000Z</StatusDate><Source id="1937131" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2017-03-01T00:00:00.000Z</StatusDate><Source id="1904977" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2017-03-01T00:00:00.000Z</StatusDate><Source id="1904977" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2017-03-01T00:00:00.000Z</StatusDate><Source id="1904977" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2017-03-01T00:00:00.000Z</StatusDate><Source id="1904977" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2013-06-18T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2013-06-18T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="28">Arthritis</Indication><StatusDate>2007-11-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1226">Age related macular degeneration</Indication><StatusDate>2013-06-18T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2009-10-09T00:00:00.000Z</StatusDate><Source id="1050268" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1226">Age related macular degeneration</Indication><StatusDate>2011-09-02T00:00:00.000Z</StatusDate><Source id="1219307" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2009-10-09T00:00:00.000Z</StatusDate><Source id="1050268" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2012-09-30T00:00:00.000Z</StatusDate><Source id="1340815" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2013-12-03T00:00:00.000Z</StatusDate><Source id="1505664" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2012-11-30T00:00:00.000Z</StatusDate><Source id="1366201" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2011-10-21T00:00:00.000Z</StatusDate><Source id="1233940" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2012-11-30T00:00:00.000Z</StatusDate><Source id="1366201" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2012-11-30T00:00:00.000Z</StatusDate><Source id="1366201" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3467">Metastatic renal cancer</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="1366194" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2014-06-30T00:00:00.000Z</StatusDate><Source id="1585061" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2006-05-16T00:00:00.000Z</StatusDate><Source id="667869" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="28">Arthritis</Indication><StatusDate>2006-05-16T00:00:00.000Z</StatusDate><Source id="667869" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1226">Age related macular degeneration</Indication><StatusDate>2006-05-16T00:00:00.000Z</StatusDate><Source id="667869" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1009646">Acceleron Pharma Inc</OwnerCompany><Country id="US">US</Country><Indication id="4250">Metastatic renal cell carcinoma</Indication><AwardedIndication>Treatment of patients with advanced renal cell carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-11-04T00:00:00.000Z</MileStoneDate><Source id="1709863" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00096"><Name>Alk-1 protein kinase</Name><SwissprotNumbers><Swissprot>P37023</Swissprot><Swissprot>P80203</Swissprot><Swissprot>Q61288</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00218"><Name>Bone morphogenetic protein-10 ligand</Name><SwissprotNumbers><Swissprot>O95393</Swissprot><Swissprot>Q9R229</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00223"><Name>Bone morphogenetic protein-9 ligand</Name><SwissprotNumbers><Swissprot>Q9UK05</Swissprot><Swissprot>Q9WV56</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01832"><Name>TGF beta receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009646">Acceleron Pharma Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="21091">Ludwig Institute for Cancer Research</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24839">Harvard Medical School</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="11">Patent - Exclusive Rights</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><Deals><Deal id="153209" title="Acceleron to license BIDMC patent rights related to dalantercept and TKIs against renal cell cancer "/><Deal id="157411" title="Acceleron to license worldwide rights of Ludwig Institute's IP related to first cloning of the type I activin receptors                                    "/></Deals><PatentFamilies><PatentFamily id="1770926" number="WO-2009139891" title="Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof"/><PatentFamily id="2713267" number="WO-2014055869" title="Treatment of cancer with ALK1 antagonists"/><PatentFamily id="2925535" number="WO-2015061666" title="Endoglin peptides to treat fibrotic diseases"/><PatentFamily id="3038072" number="WO-2015147908" title="Use of activin receptor-like kinase 1 (ALK-1) antagonists in the treatment of cancer"/><PatentFamily id="3316680" number="WO-2008057461" title="ALK1 receptor and ligand antagonists and uses thereof."/><PatentFamily id="348400" number="WO-2009134428" title="Methods and compositions for modulating angiogenesis and pericyte composition"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Delaware Capital Formation Inc" id="1004954"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Acceleron Pharma Inc" id="1009646"/><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ember Therapeutics Inc (pre-merger)" id="1066941"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alkermes plc" id="14005"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ludwig Institute for Cancer Research" id="21091"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>